A real world study to assess ICI-related cutaneous toxicities focusing on severe cutaneous adverse reactions from US Food and Drug Administration Adverse Event Reporting System
Latest Information Update: 19 Aug 2020
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Antineoplastics
- Indications Cancer
- Focus Adverse reactions
- 19 Aug 2020 New trial record